The U.S Food and Drug Administration (FDA) has issued draft guidance titled “Internet/Social Media Platforms with Character Space Limitations: Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices.” The document addresses the agency’s “current thinking on how manufacturers, packers, and distributors (firms) of prescription human and animal drugs (drugs) and medical devices for human use (devices), including biological products, that choose to present benefit information should present both benefit and risk information within advertising and promotional labeling of their FDA-regulated medical products on electronic/ digital platforms that are associated with character space limitations, specifically on the Internet and through social media or other technological venues.” Comments are requested by September 16, 2014.

FDA has also issued for public comment draft guidance titled “Internet/ Social Media Platforms: Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical Devices.” This guidance discusses how these stakeholders “should respond, if they choose to respond, to misinformation related to a firm’s own FDA-approved or cleared products when that information is created or disseminated by independent third parties, particularly on the Internet or through social media platforms. Comments on this draft guidance are requested by August 18, 2014. See Federal Register, June 18, 2014.